ロード中...
Implementing genotype-guided antithrombotic therapy
Genotyping has the potential to improve the efficacy and safety of major antithrombotic drugs. For warfarin, the stable maintenance dose varies from 1–10 mg/day. The VKORC1 −1639G>A allele and the CYP2C9*2 and *3 alleles (cumulative frequency: 90% in Asians, 65% in Europeans and 20% in Africans),...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2010
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2903229/ https://ncbi.nlm.nih.gov/pubmed/20462345 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fca.10.6 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|